By Diagnostics World News Staff
September 18, 2026 | This week Mayo Clinic announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific. Precure will create one of the world’s leading biomedical datasets by integrating proteomic, genomic, and longitudinal clinical data to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics.
Precure, LLC complements Precure Research, Mayo Clinic’s investigator-led scientific effort to understand the biological changes that occur as people move from health toward disease. Precure Research advances the science of identifying and understanding early disease signals, while Precure, LLC provides the scale, infrastructure and collaborations needed to generate population-scale molecular data and help translate discoveries into new diagnostics, therapeutics and other healthcare solutions.
Mayo Clinic will serve as the majority owner of Precure, LLC; Thermo Fisher joins the partnership as a minority owner. Mayo Clinic's involvement in Precure, LLC is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education.
Together, they contribute complementary expertise designed to generate the molecular and clinical data needed to accelerate discovery and translate new insights into advancements in patient care.
Mayo Clinic combines world-class clinical and research leadership with advanced AI and data science capabilities, extensive biospecimens and longitudinal de-identified clinical data to accelerate discovery and translate insights into advances for patients. Mayo Clinic will serve as the pathway to validate discoveries and ultimately brings meaningful advances into patient care.
Thermo Fisher brings proteomics expertise and solutions, including its proteomics platform, Olink Explore HT, and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents to help build Precure, LLC’s multi-omics ecosystem.
Connected Molecular, Clinical Data
Many diseases begin developing biologically years before symptoms lead to a clinical diagnosis. By connecting molecular and clinical data over time, Precure could help researchers better understand these early changes, accelerate drug development and create new opportunities for earlier diagnosis, intervention and more personalized care across a wide range of diseases, such as cancer, cardiometabolic disease, neurological disorders, and immune-mediated disease.
Precure will bring together molecular data generated from one million biospecimens, linked with longitudinal clinical information collected over several years, integrating genomic and proteomic information with Mayo Clinic’s clinical data and expertise in a highly standardized setting. AI and large-scale data-analytics will be integral to identifying patterns within these complex datasets and translating them into actionable insights.
“By harnessing the full potential of multi-omics data, Precure, LLC aims to help us better understand disease before symptoms appear, accelerating discoveries that can lead to earlier diagnoses, more targeted treatments and better outcomes for patients,” said Gianrico Farrugia, M.D., president and CEO, Mayo Clinic, in a press release.
“Precure LLC has the potential to create a step change in how we generate and apply multi-omics data to improve human health,” added Marc Casper, Chairman and CEO, Thermo Fisher Scientific in the same announcement. “By combining Thermo Fisher’s leadership in scientific technology with Mayo Clinic’s leadership in clinical care, research and innovation, we can create new opportunities at unprecedented scale to detect disease earlier, accelerate drug development and enable more precise therapies.”